More in this section:

Media Notice: All media representatives and photographers must be escorted by a member of our Media Relations team while on campus. Please contact Kim Savage [kim-savage@smh.com] to arrange onsite interviews or video/photo shoots of patients, staff and healthcare providers in our facilities. For non-media inquiries, please call (941) 917-7777.

SMH Opens Doors to More Visitors as COVID-19 Cases Decline

SMH Opens Doors to More Visitors as COVID-19 Cases Decline

Sarasota Memorial Hospital is opening its doors to more visitors, thanks to a drop in hospitalizations, increasing immunity from COVID-19 vaccinations and a continuing decline in cases of COVID-19 across our community and nation.

Friday, May 21, 2021
SMH Again Earns Awards for Quality and Safety

SMH Again Earns Awards for Quality and Safety

Sarasota Memorial Hospital continues to lead the region in quality and safety, earning a 5-star rating for overall quality from the federal government and another "A" for patient safety in The Leapfrog Group's hospital report cards.

Thursday, April 29, 2021
Site Planning Begins for Cancer Institute Expansion Phases 3 & 4

Site Planning Begins for Cancer Institute Expansion Phases 3 & 4

The Sarasota County Public Hospital Board this week authorized Sarasota Memorial staff to move forward with preliminary site and design plans for 2 new outpatient oncology facilities: a new, 6-story cancer pavilion on the hospital’s Sarasota campus and a 2-story cancer center on its developing Venice hospital campus.

Wednesday, April 21, 2021
SMH Joins Drug Study to Reduce Dangerous Inflammation in COVID-19 Patients

SMH Joins Drug Study to Reduce Dangerous Inflammation in COVID-19 Patients

Sarasota Memorial Hospital is one of more than a dozen research sites across the nation participating in the multi-center trial of IC14, an anti-CD14 monoclonal antibody drug that researchers hope will reduce dangerous levels of inflammation in COVID-19 patients. This week, SMH became the first U.S. site to enroll a patient in the phase 2 trial, called the COVID-19 anti-CD14 Treatment Trial (CaTT). 

Thursday, April 15, 2021
COVID-19 Treatment Offered at SMH Shows Promising Results

COVID-19 Treatment Offered at SMH Shows Promising Results

A monoclonal antibody cocktail developed by Regeneron cut the risk of hospitalization and death by 70% when given to high-risk COVID-19 patients in a large clinical trial, the drug maker announced last week. SMH was among 27 sites participating in the trial.

Wednesday, March 31, 2021
RSS
124678910Last